The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMonte Rosa Therapeutics (Nasdaq: GLUE) announced positive updated Phase 1/2 clinical data for its molecular glue degrader, MRT-2359, targeting metastatic castration-resistant prostate cancer (mCRPC). The study revealed a remarkable 100% PSA response rate in patients with specific androgen receptor mutations when MRT-2359 was combined with enzalutamide. Across the total cohort of 15 evaluable patients, the company reported a disease control rate of 67%, signaling strong efficacy in heavily pretreated cases. These results were presented at the ASCO Genitourinary Cancers Symposium, highlighting the potential of the company's therapeutic platform. Following these encouraging signals, Monte Rosa plans to initiate a new Phase 2 study in the third quarter of 2026. Investors view this clinical progress as a significant validation of the company's pipeline and its ability to address complex oncological challenges.